Close Menu

single-cell analysis

Single-nuclei RNA sequencing on more than 100,000 brain cells from individuals with or without ASD identified gene expression shifts in certain cell types.

With DNA methylation data for more than 1,800 chronic lymphocytic leukemia B cells, researchers tracked CLL epimutation rates and saw lineages with distinct treatment responses.

Researchers built a single-cell gene expression atlas of premalignant lesions and early gastric cancer to find shifts that could portend disease progression.

The Massachusetts Institute of Technology-led team uncovered cell-type-specific transcriptional changes that occur early on in disease development.

In Cell this week: DNA-based survey of marine virus genomes,  single-cell atlas of tumor proteomic profiles, and more.

The researchers dubbed the cell the found a "revival stem cell" and reported that slow-cycling cell type relies on YAP1 signaling to expand to repopulate the intestine.

Ardigen has expanded into immuno-oncology, microbiomics, epigenomics, and CRISPR data analysis to support drug development and precision medicine.

The firm will work with investigators from the University of North Carolina at Chapel Hill and the University of Virginia to validate its AIR system in CRISPR workflows.

In Genome Biology this week: genomic sequencing of milkweed bug, benchmark comparison of single-cell RNA sequencing platforms, and more.

Some of the mutational signatures the researchers observed were similar to ones previously seen in B cell tumors, underscoring the link between aging and cancer.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.